Poolbeg Pharma PLC
LSE:POLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Poolbeg Pharma PLC
Total Equity
Poolbeg Pharma PLC
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Poolbeg Pharma PLC
LSE:POLB
|
Total Equity
£9.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Total Equity
£16.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
2%
|
CAGR 10-Years
12%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Total Equity
$48.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
10%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Total Equity
$2.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Total Equity
-£28.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Total Equity
£207.6m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
Poolbeg Pharma PLC
Glance View
Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.
See Also
What is Poolbeg Pharma PLC's Total Equity?
Total Equity
9.3m
GBP
Based on the financial report for Dec 31, 2024, Poolbeg Pharma PLC's Total Equity amounts to 9.3m GBP.
What is Poolbeg Pharma PLC's Total Equity growth rate?
Total Equity CAGR 3Y
-26%
Over the last year, the Total Equity growth was -36%. The average annual Total Equity growth rates for Poolbeg Pharma PLC have been -26% over the past three years .
